Renaissance of Conventional First-Line Antibiotics in<i> Salmonella enterica</i> Clinical Isolates: Assessment of MICs for Therapeutic Antimicrobials in Enteric Fever Cases from Nepal

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Indicators </td><td class="align_center">DDST</td><td class="align_center">MIC (CIP only)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">NA and CIP sensitive isolates</td><td class="align_center">24 (27.3%)</td><td class="align_center">24 (27.3%)</td></tr><tr><td class="align_left">NA and CIP resistant isolates</td><td class="align_center">6 (6.8%)</td><td class="align_center">4 (4.5%)</td></tr><tr><td class="align_left">NA resistant and CIP intermediate isolates</td><td class="align_center">58 (65.9%)</td><td class="align_center">2 (2.3%)</td></tr><tr><td class="align_left">NA resistant and CIP sensitive isolates</td><td class="align_center">—</td><td class="align_center">58 (65.9%)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>NA: nalidixic acid, CIP: ciprofloxacin, DDST: disk diffusion susceptibility testing, and MIC: minimum inhibitory concentration.<br/></td></tr></table>

Indicators of <i>Salmonella</i> isolates with nalidixic acid and ciprofloxacin susceptibility.

BioMed Research International

tab3

Table 3

Table 3: Renaissance of Conventional First-Line Antibiotics in<i> Salmonella enterica</i> Clinical Isolates: Assessment of MICs for Therapeutic Antimicrobials in Enteric Fever Cases from Nepal 

Table 3 | Renaissance of Conventional First-Line Antibiotics in Salmonella enterica Clinical Isolates: Assessment of MICs for Therapeutic Antimicrobials in Enteric Fever Cases from Nepal 